{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:03:26Z","timestamp":1793113406482,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10928-024-09902-1","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T19:02:41Z","timestamp":1707418961000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-4463","authenticated-orcid":false,"given":"Janneke M.","family":"Brussee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7581-4525","authenticated-orcid":false,"given":"Patricia N.","family":"Sidharta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5817","authenticated-orcid":false,"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-976X","authenticated-orcid":false,"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"9902_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, Bellet M, Weber MA et al (2022) Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400:1927\u20131937. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7","journal-title":"Lancet"},{"key":"9902_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1139\/cjpp-2022-0010","volume":"100","author":"M Clozel","year":"2022","unstructured":"Clozel M (2022) Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol 100:573\u2013583. https:\/\/doi.org\/10.1139\/cjpp-2022-0010","journal-title":"Can J Physiol Pharmacol"},{"key":"9902_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411\u2013415. https:\/\/doi.org\/10.1038\/332411a0","journal-title":"Nature"},{"key":"9902_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1042\/CS20100222","volume":"119","author":"M Iglarz","year":"2010","unstructured":"Iglarz M, Clozel M (2010) At the heart of tissue: endothelin system and end-organ damage. Clin Sci 119:453\u2013463. https:\/\/doi.org\/10.1042\/CS20100222","journal-title":"Clin Sci"},{"key":"9902_CR5","doi-asserted-by":"publisher","unstructured":"Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14. https:\/\/doi.org\/10.1016\/s0895-7061(01)02074-x. :83S-89S","DOI":"10.1016\/s0895-7061(01)02074-x"},{"key":"9902_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/jpet.118.253864","volume":"368","author":"F Trensz","year":"2019","unstructured":"Trensz F, Bortolamiol C, Kramberg M et al (2019) Pharmacological characterization of Aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the Renin Angiotensin System, in two models of experimental hypertension. J Pharmacol Exp Ther 368:462\u2013473. https:\/\/doi.org\/10.1124\/jpet.118.253864","journal-title":"J Pharmacol Exp Ther"},{"key":"9902_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","volume":"75","author":"P Verweij","year":"2020","unstructured":"Verweij P, Danaietash P, Flamion B et al (2020) Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension 75:956\u2013965","journal-title":"Hypertension"},{"key":"9902_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/DDDT.S199051","volume":"13","author":"P Sidharta","year":"2019","unstructured":"Sidharta P, Melchior M, Kankam MK, Dingemanse J (2019) Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Devel Ther Volume 13:949\u2013964. https:\/\/doi.org\/10.2147\/DDDT.S199051","journal-title":"Drug Des Devel Ther Volume"},{"key":"9902_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2174\/1389200222666210204202815","volume":"22","author":"PN Sidharta","year":"2021","unstructured":"Sidharta PN, Fischer H, Dingemanse J (2021) Absorption, distribution, metabolism, and excretion of Aprocitentan, a dual endothelin receptor antagonist, in humans. Curr Drug Metab 22:399\u2013410. https:\/\/doi.org\/10.2174\/1389200222666210204202815","journal-title":"Curr Drug Metab"},{"key":"9902_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40261-019-00837-x","volume":"39","author":"PN Sidharta","year":"2019","unstructured":"Sidharta PN, Ul\u010d I, Dingemanse J (2019) Single-dose pharmacokinetics and tolerability of Aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment. Clin Drug Investig 39:1117\u20131123. https:\/\/doi.org\/10.1007\/s40261-019-00837-x","journal-title":"Clin Drug Investig"},{"key":"9902_CR11","doi-asserted-by":"publisher","first-page":"19067","DOI":"10.1038\/s41598-022-22470-z","volume":"12","author":"MSC Fontes","year":"2022","unstructured":"Fontes MSC, Dingemanse J, Halabi A et al (2022) Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Sci Rep 12:19067. https:\/\/doi.org\/10.1038\/s41598-022-22470-z","journal-title":"Sci Rep"},{"key":"9902_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13318-019-00590-8","volume":"45","author":"PN Sidharta","year":"2020","unstructured":"Sidharta PN, Dingemanse J (2020) Effect of multiple-dose Aprocitentan Administration on the pharmacokinetics of midazolam in healthy male subjects. Eur J Drug Metab Pharmacokinet 45:227\u2013234. https:\/\/doi.org\/10.1007\/s13318-019-00590-8","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"9902_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/cpdd.815","volume":"9","author":"PN Sidharta","year":"2020","unstructured":"Sidharta PN, Dingemanse J (2020) Effects of multiple-dose administration of Aprocitentan on the pharmacokinetics of Rosuvastatin. Clin Pharmacol Drug Dev 9:995\u20131002. https:\/\/doi.org\/10.1002\/cpdd.815","journal-title":"Clin Pharmacol Drug Dev"},{"key":"9902_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/cpdd.881","volume":"10","author":"MSC Fontes","year":"2021","unstructured":"Fontes MSC, Dingemanse J, Sidharta PN (2021) Multiple-dose pharmacokinetics, Safety, and tolerability of Aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and caucasian subjects. Clin Pharmacol Drug Dev 10:718\u2013725. https:\/\/doi.org\/10.1002\/cpdd.881","journal-title":"Clin Pharmacol Drug Dev"},{"key":"9902_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11606-011-1829-z","volume":"27","author":"MA Raebel","year":"2012","unstructured":"Raebel MA, Ellis JL, Carroll NM et al (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27:57\u201364. https:\/\/doi.org\/10.1007\/s11606-011-1829-z","journal-title":"J Gen Intern Med"},{"key":"9902_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cpt.2043","volume":"109","author":"P Gueneau de Mussy","year":"2021","unstructured":"Gueneau de Mussy P, Sidharta PN, Wuerzner G et al (2021) Effects of the dual endothelin receptor antagonist Aprocitentan on Body Weight and Fluid Homeostasis in healthy subjects on a high Sodium Diet. Clin Pharmacol Ther 109:746\u2013753. https:\/\/doi.org\/10.1002\/cpt.2043","journal-title":"Clin Pharmacol Ther"},{"key":"9902_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpdd.1151","volume":"11","author":"PN Sidharta","year":"2022","unstructured":"Sidharta PN, Brussee JM, Schultz A et al (2022) ACCP Abstract Booklet. Clin Pharmacol Drug Dev 11:1\u2013112. https:\/\/doi.org\/10.1002\/cpdd.1151","journal-title":"Clin Pharmacol Drug Dev"},{"key":"9902_CR18","unstructured":"Idorsia Pharmaceuticals Ltd (2022) Bioequivalence Study of Different Aprocitentan Tablet Formulations. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05196399. Accessed 26 Jun 2023"},{"key":"9902_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481\u2013504. https:\/\/doi.org\/10.1023\/A:1012299115260","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9902_CR20","unstructured":"Lixoft (2021) Monolix documentation"},{"key":"9902_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1214\/aos\/1018031103","volume":"27","author":"B Delyon","year":"1999","unstructured":"Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann Stat 27:94\u2013128","journal-title":"Ann Stat"},{"key":"9902_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Breyer Lewis J et al (1999) A more Accurate Method to Estimate glomerular filtration rate from serum creatinine: a New Prediction equation. Ann Intern Med 130:461. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med"},{"key":"9902_CR23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-145-4-200608150-00004","journal-title":"Ann Intern Med"},{"key":"9902_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/psp4.12612","volume":"10","author":"G Ayral","year":"2021","unstructured":"Ayral G, Si Abdallah J, Magnard C, Chauvin J (2021) A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: the COSSAC approach. CPT Pharmacometrics Syst Pharmacol 10:318\u2013329. https:\/\/doi.org\/10.1002\/psp4.12612","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9902_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1214\/14-EJS890","volume":"8","author":"M Delattre","year":"2014","unstructured":"Delattre M, Lavielle M, Poursat MA (2014) A note on BIC in mixed-effects models. Electron J Stat 8:456\u2013475. https:\/\/doi.org\/10.1214\/14-EJS890","journal-title":"Electron J Stat"},{"key":"9902_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/psp.2014.13","volume":"3","author":"A Krause","year":"2014","unstructured":"Krause A, Lowe P (2014) Visualization and communication of pharmacometric models with Berkeley Madonna. CPT Pharmacometrics Syst Pharmacol 3:116. https:\/\/doi.org\/10.1038\/psp.2014.13","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9902_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/psp4.12757","volume":"11","author":"FV Marcoline","year":"2022","unstructured":"Marcoline FV, Furth J, Nayak S et al (2022) Berkeley Madonna Version 10\u2013A simulation package for solving mathematical models. CPT Pharmacometrics Syst Pharmacol 11:290\u2013301. https:\/\/doi.org\/10.1002\/psp4.12757","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9902_CR28","unstructured":"R (2020) R: a Language and Environment for Statistical Computing. Version 3.6.1 and 4.0.4, 2002, R Foundation for Statistical Computing"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09902-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09902-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09902-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:21:26Z","timestamp":1716999686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09902-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["9902"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09902-1","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of analysis conduct, J.M.B., P.S., J.D., and A.K. were employees and\/or shareholders of Idorsia Pharmaceuticals Ltd which develops aprocitentan as treatment for resistant hypertension.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}